540 patients with metastatic HER2+ breast cancer received either capecitabine plus lapatinib or capecitabine plus trastuzumab in the third CEREBEL study (Patel et al., 2020; Tan et al., 2021). Here, ERBB2 is linked to breast carcinoma.